Neoadjuvant nivolumab improves long-term survival for lung cancer
Analysis of a Phase II trial for non-small cell lung cancer has suggested neoadjuvant nivolumab improved five-year recurrence-free survival.
Source: europeanpharmaceuticalreview.com
Macmillan Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Macmillan Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Macmillan Foundation Today - Breaking & Trending Today
Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients
Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Source: news-medical.net